Thursday, October 21, 2021 2:14:08 PM
nanalysis logo (CNW Group/Nanalysis Scientific Corp.)
The purchase and payment for the Common Shares will be made by Nanalysis through the facilities of the TSX Venture Exchange. Research Capital Corp has been selected as Nanalysis' agent for the NCIB. The price paid for the Common Shares will be, subject to NCIB pricing rules contained in securities laws, the prevailing market price of such Common Shares on the TSX Venture Exchange at the time of such purchase. Nanalysis intends to fund the purchases out of available cash.
Nanalysis believes that the market price of its Common Shares may not reflect their underlying value and the Board of Directors has authorized this initiative because, in the Board's opinion, the proposed purchase of Common Shares pursuant to the NCIB could constitute an appropriate use of Nanalysis' funds, and the repurchase of its Common Shares is one way of creating shareholder value and provides corporate flexibility.
To the knowledge of Nanalysis, no director, senior officer or other insider of the Nanalysis currently intends to sell any Common Shares under the NCIB. However, sales by such persons through the facilities of the TSX Venture Exchange may occur if the personal circumstances of any such person changes or any such person makes a decision unrelated to these NCIB purchases. The benefits to any such person whose Common Shares are purchased would be the same as the benefits available to all other holders whose Common Shares are purchased.
•
Recent NSCI News
- Nanalysis Announces Fourth Quarter and Full Year 2023 Results • PR Newswire (Canada) • 04/29/2024 08:05:00 PM
- /C O R R E C T I O N -- Nanalysis Scientific Corp./ • PR Newswire (Canada) • 04/24/2024 12:30:00 PM
- Nanalysis Announces Full Year 2023 Conference Call • PR Newswire (Canada) • 04/11/2024 12:30:00 PM
- Nanalysis Scientific Corp. Announces Director Resignation • PR Newswire (Canada) • 04/10/2024 01:55:00 PM
- AI Revolutionizes Drug Detection with Compact NMR and Machine Learning • AllPennyStocks.com • 04/04/2024 02:30:00 PM
- Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances • PR Newswire (Canada) • 04/04/2024 12:30:00 PM
- NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT • PR Newswire (Canada) • 03/20/2024 01:32:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NSCI • PR Newswire (Canada) • 03/06/2024 09:17:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - NSCI • PR Newswire (Canada) • 03/06/2024 09:15:00 PM
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NSCI • PR Newswire (Canada) • 03/06/2024 09:10:00 PM
- Canadian Investment Regulatory Organization Trading Halt - NSCI • PR Newswire (Canada) • 03/06/2024 09:07:00 PM
- NANALYSIS ANNOUNCES UP TO $5.0 MILLION BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND UP TO $1.0 MILLION CONCURRENT PRIVATE PLACEMENT • PR Newswire (Canada) • 03/06/2024 09:00:00 PM
- Nanalysis Announces Upcoming Webinar and Conference Participation • PR Newswire (Canada) • 02/07/2024 01:30:00 PM
- Nanalysis Achieves Record Revenue in Q4 • PR Newswire (Canada) • 02/06/2024 01:30:00 PM
- Nanalysis Scientific Corp. Provides Update on Security Services Business • PR Newswire (Canada) • 01/30/2024 01:30:00 PM
- Nanalysis Scientific Corp. Announces Grant of Restricted Share Units • PR Newswire (Canada) • 01/04/2024 12:11:00 AM
- Nanalysis Reports Third Quarter 2023 Results • PR Newswire (Canada) • 11/29/2023 10:19:00 PM
- Nanalysis Announces Third Quarter 2023 Conference Call • PR Newswire (Canada) • 11/15/2023 01:30:00 PM
- Nanalysis to Present at the Planet MicroCap Showcase: VANCOUVER 2023 on Wednesday, September 6, 2023 & 1x1 Meetings on Thursday, September 7, 2023 • PR Newswire (Canada) • 08/30/2023 12:30:00 PM
- Nanalysis Reports Second Quarter 2023 Results • PR Newswire (Canada) • 08/24/2023 08:05:00 PM
- Nanalysis Announces Second Quarter 2023 Conference Call • PR Newswire (Canada) • 08/15/2023 12:30:00 PM
- TSX Venture Exchange Stock Maintenance Bulletins • PR Newswire (Canada) • 06/30/2023 10:23:00 PM
- Nanalysis Enters into New Credit Facility with ATB Financial • PR Newswire (Canada) • 06/29/2023 11:40:00 PM
- Nanalysis To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar • PR Newswire (Canada) • 06/20/2023 08:05:00 PM
- Nanalysis Announces Annual General Meeting • PR Newswire (Canada) • 06/15/2023 01:07:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM